← Back to Screener
BiomX Inc. (PHGE)
Price$1.46
Favorite Metrics
Price vs S&P 500 (26W)-92.17%
Price vs S&P 500 (4W)-71.87%
Market Capitalization$12.04M
All Metrics
Book Value / Share (Quarterly)$7.43
P/TBV (Annual)1.10x
Cash Flow / Share (Quarterly)$-16.56
Price vs S&P 500 (YTD)-5.74%
EPS (TTM)$-17.72
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$-17.72
EPS (Annual)$-22.19
ROI (Annual)-73.41%
Cash / Share (Quarterly)$2.74
ROA (Last FY)-625.96%
EBITD / Share (TTM)$-4.64
ROE (5Y Avg)-237.19%
Cash Flow / Share (Annual)$-16.56
P/B Ratio1.15x
P/B Ratio (Quarterly)1.34x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-22.79x
ROA (TTM)-125.20%
EPS Incl Extra (Annual)$-22.19
Current Ratio (Annual)0.87x
Quick Ratio (Quarterly)0.82x
3-Month Avg Trading Volume0.75M
52-Week Price Return-82.08%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.11
52-Week High$14.71
EPS Excl Extra (Annual)$-22.19
CapEx CAGR (5Y)-71.20%
26-Week Price Return-83.42%
Quick Ratio (Annual)0.82x
13-Week Price Return-30.30%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.87x
Enterprise Value$7.68
Book Value / Share Growth (5Y)46.87%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.74
3-Month Return Std Dev226.62%
Net Income / Employee (TTM)$-2
ROE (Last FY)-73.41%
Net Interest Coverage (Annual)-15.30x
EPS Basic Excl Extra (Annual)$-22.19
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-17.72
ROI (TTM)-190.95%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$12.65
Price vs S&P 500 (52W)-117.18%
Year-to-Date Return-1.60%
5-Day Price Return-30.04%
EPS Normalized (Annual)$-22.19
ROA (5Y Avg)-176.03%
Month-to-Date Return-50.99%
Cash Flow / Share (TTM)$-0.58
EBITD / Share (Annual)$-20.94
LT Debt / Equity (Annual)1.75x
ROI (5Y Avg)-89.30%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-17.72
P/TBV (Quarterly)1.67x
P/B Ratio (Annual)0.55x
Book Value / Share (Annual)$25.24
Price vs S&P 500 (13W)-33.17%
Beta1.32x
Revenue / Share (TTM)$0.00
ROE (TTM)-190.95%
52-Week Low$1.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.00
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PHGEBiomX Inc. | — | — | — | — | $1.46 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
BiomX develops personalized phage-based treatments for chronic bacterial infections using its proprietary BOLT platform to customize phage cocktails against specific pathogens. The company's pipeline includes BX004 for pseudomonas infections in cystic fibrosis patients and BX211 for diabetic foot osteomyelitis, addressing significant unmet needs where traditional antibiotics face efficacy challenges.